Clinical Phenotypes, Treatment, and Outcomes of Rheumatic Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors: A Rheumatologists-Referred Multicenter German Registry Cohort. [PDF]
Gailis D +14 more
europepmc +1 more source
Mepce Restrains Ferroptosis in Prostate Cancer Through 7SK–P‐TEFb Pause Control
Genome‐wide CRISPR screening identifies MEPCE as a pause‐control regulator that restrains ferroptosis in prostate cancer. MEPCE loss releases P‐TEFb/CDK9 from 7SK snRNP control, enhances RNAPII Ser2 phosphorylation, and accelerates NRF2‐HMOX1‐driven labile iron accumulation and lipid peroxidation, revealing a transcriptional kinetic gate that lowers ...
Tongtong Zhang +9 more
wiley +1 more source
Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy. [PDF]
Qiu Y +7 more
europepmc +1 more source
VEGFR‐2 signaling in OSCC activates Src–STAT6‐dependent CSF2 transcription, driving tumor‐derived GM‐CSF secretion. GM‐CSF programs neutrophils to express PD‐L1 through STAT5–mTOR/S6K signaling, suppressing cytotoxic CD8+ T cells. This pathway reveals a tumor–neutrophil immune checkpoint circuit that limits anti‐PD‐1 responsiveness in OSCC.
Fangxing Zhu +13 more
wiley +1 more source
Checkpoint inhibitor-induced hematologic immune-related adverse events and their association with disease recurrence in hematolymphoid malignancies: a clinical perspective. [PDF]
Ben Lamine C +5 more
europepmc +1 more source
FBL directly binds to and stabilizes SIRT1 by blocking its ubiquitin‐proteasome degradation, thereby sustaining nicotinamide metabolism and redox homeostasis to counteract cellular senescence in ESCC. Genetic and pharmacological suppression of FBL sensitizes tumor cells to senolytic therapy.
Xing Jin +9 more
wiley +1 more source
Unveiling the Scientific Landscape and Trends of Cutaneous Immune-Related Adverse Events: A Bibliometric Analysis. [PDF]
Zhong D, Shi C.
europepmc +1 more source
A Novel Pak1 Activator Ameliorates ER Stress for HFpEF Therapy
Chronic metabolic stress is a major contributor to HFpEF progression. Under prolonged metabolic stress, Pak1 activity becomes impaired, contributing to disrupted ER proteostasis, cardiomyocyte apoptosis, fibrosis, and diastolic dysfunction. Mechanistically, Pak1 overexpression activates the ERK1/2–MNK1–eIF4E signaling axis, promotes translational ...
Honglin Xu +17 more
wiley +1 more source
Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis. [PDF]
Zarańska K +4 more
europepmc +1 more source
High glucose is linked to reduced succinate dehydrogenase activity in CD14+ monocytes, accompanied by succinate accumulation and extracellular release. Extracellular succinate exacerbates mitochondrial ROS production and mtDNA release in CD4+ T cells. Cytosolic mtDNA then activates Z‐DNA binding protein 1 (ZBP1) and engages ZBP1‐associated inflammatory
Shuai Zhao +11 more
wiley +1 more source

